Overview

Phase I Study on Multiple Oral Dosing of CG100649

Status:
Completed

Trial end date:
2011-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of 3 escalating loading and maintenance dose regimens of CG100649 administered orally for 7 total days in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

CrystalGenomics, Inc.

Treatments:

Naproxen